Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Int J Risk Saf Med ; 35(3): 233-245, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38943400

RESUMEN

BACKGROUND: The ubiquity of social media has ushered in an era where uncontrolled content sharing extends to all subjects, including sensitive topics such as medication consumption. OBJECTIVE: To quantify the prevalence of YouTube videos providing information on glucocorticoids and to underscore the risks associated with inaccurate information, which might inadvertently promote inappropriate use of these medications. METHODS: The YouTube videos were selected using predefined keywords from February 20 to March 4, 2023. The videos were categorized into two groups. Category 1 promotes the misuse of corticosteroids, while Category 2 raises awareness about the risks associated with these drugs. RESULTS: In total, 843 YouTube videos were included. Approximately 76% of the creators were women. Of these, category 1 videos (69.63%) predominated over Category 2 videos (30.37%). Regarding Category 1, dexamethasone was mentioned in 41.53% of cases, followed by hydrocortisone (17.30%). According to these YouTubers, these products/medications are mainly obtained from community pharmacies (58.09%), online shops (20.01%), and through illicit markets and the black market (13.46%). Weight gain was the most common objective, according to 32.62% of the YouTubers. CONCLUSION: This study highlights the prevalence of YouTube videos regarding the misuse of corticosteroids. The common focus on weight gain as an objective underscores the importance of educating content creators and viewers about responsible corticosteroid use. Targeted interventions are needed to promote safe and informed medication practices within this online environment.


Asunto(s)
Medios de Comunicación Sociales , Humanos , Medios de Comunicación Sociales/estadística & datos numéricos , Femenino , Árabes/estadística & datos numéricos , Corticoesteroides/uso terapéutico , Corticoesteroides/administración & dosificación , Masculino , Grabación en Video , Adulto , Glucocorticoides/administración & dosificación , Glucocorticoides/uso terapéutico
2.
Curr Drug Saf ; 19(4): 431-443, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38204274

RESUMEN

Tumor necrosis factor alpha (TNF- α) inhibitors are widely employed for the management of chronic inflammatory rheumatism. However, their usage carries significant risks, including site and infusion reactions, serious infections, malignancy, heart failure autoimmune and demyelinating disorders. These risks are comprehensively outlined in risk management plans (RMPs) associated with these molecules. RMP provides information on the safety profile of a medicinal product as well as the measures that will be taken to minimize risks; these are known as risk minimization measures. These measures are divided into routine measures related to elements, such as the summary of product characteristics, labeling, pack size, package leaflet, or legal supply status of the product, while additional measures may include educational programs, including tools for healthcare providers and patients, controlled access or pregnancy prevention programs, among others. Additional measures can consist of one or more interventions that need to be implemented in a sustainable way in a defined target group, while respecting the timing and frequency of any intervention and procedures to reach the target population. An evaluation of the effectiveness of these measures is required to determine whether or not an intervention has been effective. This comprehensive review offers an in-depth exploration of the current treatment, uses, and associated risks of TNF-α inhibitors. Additionally, it provides a detailed account of risk minimization measures and risk management practices while shedding light on their real-world implementation and effectiveness.


Asunto(s)
Antirreumáticos , Enfermedades Reumáticas , Factor de Necrosis Tumoral alfa , Humanos , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Enfermedades Reumáticas/tratamiento farmacológico , Antirreumáticos/efectos adversos , Antirreumáticos/uso terapéutico , Gestión de Riesgos/métodos , Enfermedad Crónica
3.
Ann Pharm Fr ; 82(3): 392-400, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38218427

RESUMEN

Chronic kidney disease (CKD) is one of the non-infectious diseases that threaten patients' lives on a daily basis. Its prevalence is high, but under-reported by patients and those living with the disease, as it is silent and asymptomatic in the early stages. Kidney disease increases the risk of heart and vascular disease. These problems can manifest themselves slowly, over a long period of time. Early detection and treatment can often prevent chronic kidney disease from worsening. As kidney disease progresses, it can lead to kidney failure, requiring dialysis or a kidney transplant to stay alive. In this narrative review, we will mainly discuss different treatment option costs in different countries and how much they cost healthcare systems in countries in three different continents.


Asunto(s)
Diálisis Renal , Insuficiencia Renal Crónica , Humanos , Insuficiencia Renal Crónica/epidemiología , Insuficiencia Renal Crónica/terapia , África/epidemiología , Costos de la Atención en Salud , Asia/epidemiología
4.
Pan Afr Med J ; 32: 89, 2019.
Artículo en Francés | MEDLINE | ID: mdl-31223380

RESUMEN

In our country, the use of traditional medicinal recipes and artisan cosmetic products is very frequent due to the high rate of illiteracy, low purchasing power and of the large number of herbalists. Camphor is a low-cost product, easily accessible and omnipresent in almost every home, making it potentially toxic in case of misuse, in particular among children. We here report two cases of intoxication induced by beauty recipe made with powdered camphor. Patients' medical history gave informations about poisoning in 2 children caused by synthetic powder made with camphor imported from China. Patient 1: little girl aged 2 months, with no previous medical history, admitted to the Emergency Department due to constant crying and refusal to eat. Clinical examination showed no abnormalities. Standard laboratory tests were normal. Neurological, digestive and cutaneous monitoring were performed. Patient 2: girl aged 6 years admitted with atonic seizure associated with syncope and foaming followed by abdominal pain and vomiting after ingesting milk. The evolution was favorable 48 hours after symptom management. Mothers reported two neighbors had received a traditional hair care recipe by a third neighbor. After that they had mixed powdered camphor with olive oil, then they had applied it to the hair of their children for one hour, thus causing the occurrence of these symptoms.


Asunto(s)
Alcanfor/envenenamiento , Preparaciones para el Cabello/envenenamiento , Dolor Abdominal/inducido químicamente , Alcanfor/administración & dosificación , Niño , Femenino , Humanos , Lactante , Convulsiones/inducido químicamente , Síncope/inducido químicamente
5.
Pan Afr Med J ; 26: 48, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28451026

RESUMEN

The objective of this work is to demonstrate the interest of integration of pharmacovigilance in Moroccan Tuberculosis Control Program (MTCP). The integration of pharmacovigilance in MTCP was conducted in October 2012with the Global Fund support. We compared the reports notified before and after this integration (period 1: January 2010-October2012; period 2: October 2012-December 2013). The detection of signals was based on the Information Component available inVigiMine. We used the SPSS version 10.0 and Med Calc version 7.3 for data analysis. The average number of spontaneous reports increased from 3.6 to 37.4 cases/month (P< 10-3). The average age was 40.7 ± 17.5 years; the sex ratio was 0.8. Hepatic reactions (32.7%) predominated during the first period, while skin reactions (24.1%) were in the second period (P = 10-4), and40.9% of cases in the first period were serious against 15.8% in second period (P = 0.003). Nine signals were generated (hepaticenzyme increase, cholestasis, jaundice, arthralgia, acne, lower limb edema, pruritus, skin rashes, and vomiting). The integration of pharmacovigilance in Moroccan Tuberculosis Control Program improved the management of ADRs and detected new signals of antituberculosis drugs.


Asunto(s)
Antituberculosos/efectos adversos , Farmacovigilancia , Tuberculosis/prevención & control , Adulto , Sistemas de Registro de Reacción Adversa a Medicamentos , Anciano , Antituberculosos/administración & dosificación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Marruecos , Programas Nacionales de Salud , Adulto Joven
6.
Pan Afr Med J ; 25: 10, 2016.
Artículo en Francés | MEDLINE | ID: mdl-28154702

RESUMEN

INTRODUCTION: The therapeutic drug monitoring (TDM) of antiepileptic drugs is a tool widely used in the management of epilepsy. In Morocco, this monitoring is carried out by the Centre Anti Poison et Pharmacovigilance (CAPM) since April 1995. METHODS: This is a retrospective study spanning 20 years. It concerns the therapeutic drug monitoring of Phenobarbital (PB) of carbamazepine (CBZ) and valproic acid (VPA). RESULTS: Therapeutic drug monitoring of the 3 antiepileptic drugs represent 58.85% of all applications received by the CAPM. The dosage of PB was ranked first followed by that of CBZ and finally by the VPA. Weak demand for therapeutic drug monitoring in Morocco could be explained by the low number of neurologists in addition to social factors. With its affordable price by patients, PB is the most prescribed antiepileptic drug in our country, which explains the high demand for its dosage. As for the therapeutic drug monitoring of the antiepileptic drug, they were mainly related to age, the occurrence of adverse effects, the association antiepileptic drugs or in the case of verification of patient compliance. CONCLUSION: Efforts are required for promoting the interests of therapeutic drug monitoring of antiepileptic drug in the management of epilepsy in Morocco.


Asunto(s)
Carbamazepina/administración & dosificación , Monitoreo de Drogas/métodos , Fenobarbital/administración & dosificación , Ácido Valproico/administración & dosificación , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/efectos adversos , Anticonvulsivantes/uso terapéutico , Carbamazepina/efectos adversos , Carbamazepina/uso terapéutico , Relación Dosis-Respuesta a Droga , Epilepsia/tratamiento farmacológico , Humanos , Cumplimiento de la Medicación , Marruecos , Fenobarbital/efectos adversos , Fenobarbital/uso terapéutico , Estudios Retrospectivos , Ácido Valproico/efectos adversos , Ácido Valproico/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA